我們已在上線！進一步了解

Seaport Therapeutics

SPTX

市值 US$9.5億

17.83 USD

+0.23

1.31%

收盤時已更新 10月16日下午4:00 EDT

盤前交易

盤後交易

18.09

+0.26

1.46%

1天

1.31%

5天

-1.71%

1個月

-19.47%

3個月

-8.66%

6個月

-10.13%

今年迄今

-10.13%

1年

-10.13%

5年

-10.13%

10年

-10.13%

關於： Seaport Therapeutics Inc is a clinical-stage therapeutics company. The company focuses on invention and development of new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. The company identified clinically validated mechanisms with established efficacy and safety profiles, historically limited by high first-pass metabolism, low bioavailability, and side effects. The company's pipeline products are based on Glyph, company's lymphatic-targeting prodrug technology is designed to bypass first-pass metabolism and thereby enhance a drug's oral bioavailability and reduce side effects.

醫療保健生物科技

新聞

正面

中性

負面

市場情緒 3個月

正面 8.3%

中性 91.7%

負面 0%

PureTech Founded Entity Seaport Therapeutics Presents Additional Pharmacokinetic Data from Phase 1 Clinical Trial of GlyphAgo™ at the 39th European College of Neuropsychopharmacology (ECNP) Congress

BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Seaport Therapeutics Presents Data from Phase 1 Trial of GlyphAgo at European College of Neuropsychopharmacology Congress.

PureTech Founded Entity Seaport Therapeutics Presents Additional Pharmacokinetic Data from Phase 1 Clinical Trial of GlyphAgo™ at the 39th European College of Neuropsychopharmacology (ECNP) Congress

Seaport Therapeutics Presents Additional Pharmacokinetic Data from Phase 1 Clinical Trial of GlyphAgo™ at the 39th European College of Neuropsychopharmacology (ECNP) Congress

BOSTON--(BUSINESS WIRE)--Seaport Therapeutics, Inc. (Nasdaq: SPTX) (“Seaport” or the “Company”), a clinical-stage therapeutics company developing novel neuropsychiatric medicines, today announced the presentation of Phase 1 clinical data for GlyphAgo™ (SPT-320 or Glyph Agomelatine) at the 39th European College of Neuropsychopharmacology (ECNP) Congress, taking place October 10-13, 2026, in Munich, Germany. The poster represents the first scientific presentation of data from the GlyphAgo Phase 1.

Seaport Therapeutics Presents Additional Pharmacokinetic Data from Phase 1 Clinical Trial of GlyphAgo™ at the 39th European College of Neuropsychopharmacology (ECNP) Congress

PureTech Founded Entity Seaport Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgo™ in Patients with Generalized Anxiety Disorder and Sleep Disturbance

BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Seaport Therapeutics Doses First Patient in GlyphAgo Phase 2a Trial in Generalized Anxiety Disorder & Sleep Disturbance.

PureTech Founded Entity Seaport Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgo™ in Patients with Generalized Anxiety Disorder and Sleep Disturbance

Seaport Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgoTM in Patients with Generalized Anxiety Disorder and Sleep Disturbance

BOSTON--(BUSINESS WIRE)--Seaport Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgo in Patients with Generalized Anxiety Disorder & Sleep Disturbance.

Seaport Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgoTM in Patients with Generalized Anxiety Disorder and Sleep Disturbance

Seaport Therapeutics to Participate in September Investor Conferences

BOSTON--(BUSINESS WIRE)--Seaport Therapeutics, Inc. (Nasdaq: SPTX) (“Seaport” or the “Company”), a clinical-stage therapeutics company that is inventing and developing novel neuropsychiatric medicines, today announced that members of its management team will participate in a series of additional upcoming investor conferences in September, including a company presentation and panel discussion featuring Co-Founder and Chief Executive Officer, Daphne Zohar, at the Goldman Sachs Life Sciences Sympo.

Seaport Therapeutics to Participate in September Investor Conferences

Seaport Therapeutics, Inc. (SPTX) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Seaport Therapeutics, Inc. (SPTX) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Seaport Therapeutics, Inc. (SPTX) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

PureTech Founded Entity Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers

BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo in Healthy Volunteers.

PureTech Founded Entity Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers

Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers

BOSTON--(BUSINESS WIRE)--Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers.

Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers

Seaport Therapeutics to Present at Citi's 2026 Biopharma Back to School Conference and Participate in 21st Annual Wells Fargo Healthcare Conference

BOSTON--(BUSINESS WIRE)--Seaport Therapeutics to present at Citi's 2026 Biopharma Back to School Conference and participate in 21st Annual Wells Fargo Healthcare Conference.

Seaport Therapeutics to Present at Citi's 2026 Biopharma Back to School Conference and Participate in 21st Annual Wells Fargo Healthcare Conference

24/7 Wall Street

Why Bristol Myers, Johnson & Johnson and More Are Watching Seaport After IPO

Seaport Therapeutics (NASDAQ:SPTX) opened at $25.44 on August 20, 2026, carrying a market capitalization of roughly $1.4 billion.

Why Bristol Myers, Johnson & Johnson and More Are Watching Seaport After IPO

查看新聞排名

價格圖表採用Lightweight Charts™實作